Cargando…
The Effect of Glatiramer Acetate on Spinal Cord Volume in Relapsing‐Remitting Multiple Sclerosis
BACKGROUND: Spinal cord atrophy occurs early in the multiple sclerosis (MS) disease course, is closely related to physical disability, and is a putative neuroprotective therapeutic outcome measure. OBJECTIVE: This pilot study explored glatiramer acetate (GA)’s effect on spinal cord volume in patient...
Autores principales: | Singhal, Tarun, Tauhid, Shahamat, Hurwitz, Shelley, Neema, Mohit, Bakshi, Rohit |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5248648/ https://www.ncbi.nlm.nih.gov/pubmed/27466943 http://dx.doi.org/10.1111/jon.12378 |
Ejemplares similares
-
The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis
por: Dupuy, Sheena L., et al.
Publicado: (2016) -
Brain and spinal cord MRI lesions in primary progressive vs. relapsing-remitting multiple sclerosis
por: Dastagir, Akram, et al.
Publicado: (2018) -
Glatiramer Acetate Treatment Normalizes Deregulated microRNA Expression in Relapsing Remitting Multiple Sclerosis
por: Waschbisch, Anne, et al.
Publicado: (2011) -
B-Cell Activity Predicts Response to Glatiramer Acetate and Interferon in Relapsing-Remitting Multiple Sclerosis
por: Tacke, Sabine, et al.
Publicado: (2021) -
Cost analysis of glatiramer acetate vs. fingolimod for the treatment of patients with relapsing-remitting multiple sclerosis in Spain
por: Sanchez-de la Rosa, Rainel, et al.
Publicado: (2013)